181141-39-9

Usage

Uses

Used in Pharmaceutical Industry:
Sevelamer carbonate is used as a pharmaceutical agent for the management of hyperphosphatemia in patients with chronic kidney disease. It operates by binding to phosphate ions in the digestive system, which in turn reduces the absorption of these ions into the bloodstream, aiding in the control of phosphate levels and the prevention of related complications.
Used in Chronic Kidney Disease Management:
In the context of chronic kidney disease, sevelamer carbonate is employed as a critical component of therapy to address hyperphosphatemia. By managing phosphate levels, it helps in reducing the risk of complications associated with kidney disease, thus playing a significant role in the overall treatment strategy for patients with impaired kidney function.
It is typically administered orally and is available in tablet form or as a powder for suspension, allowing for flexibility in dosage and administration based on individual patient needs. Adherence to prescribed dosage and instructions is essential to ensure the therapeutic effectiveness of sevelamer carbonate and to minimize potential side effects.

Upstream product

• 152673-18-2 (S)-N-benzyl-5-methylpyrrolidin-3-one 
• 74880-19-6 (S)-1-Benzyl-5-methyl-pyrrolidin-3-ylamine 
• 152673-20-6 (3S,5S)-1-Benzyl-5-methyl-pyrrolidin-3-ylamine 
• 152673-19-3 (3R,5S)-1-Benzyl-5-methyl-pyrrolidin-3-ol 
• 74880-19-6 methyl-(2S,4R)-4-amino-1-benzylpyrrolidine 
• 74880-19-6 C₁₂H₁₈N₂ 
• 173066-70-1 (S)-3-Amino-1-benzyl-5-methyl-4,5-dihydro-1H-pyrrole-2-carbonitrile 
• 152673-17-1 (3S)-⁽³⁾-Benzyl-(cyanomethyl)aminobutanonitrile 
• 139161-74-3 (2S,4S)-4-t-butoxycarbonylamino-2-methyl-1-N-benzylpyrrolidine 

Relevant academic research and scientific papers

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

Disclosed are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also disclosed are pharmaceutical compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

Provided are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also provided are pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Quinolizinone type compounds

Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

A practical stereoselective synthesis of (2S, 4S)-4-tert-butoxycarbonylamino-2-methylpyrrolidine

Two practical syntheses of (2S, 4S)-4-tert-butoxycarbonylamino-2-methylpyrrolidine, an important intermediate for quinolone antibacterial agents, have been developed through the combination of diastereo and enantioselective reactions starting from ethyl crotonate and L-alanine, respectively.

Quinobenzoxazine, antineoplastic agents

Quinobenzoxazine, derivatives of the formula STR1 as well as the pharmaceutically acceptable salts, esters, amides and prodrugs thereof are disclosed, wherein R1 is hydrogen or a carboxy-protecting group, R2 and R3 are substitutents, A is oxygen, Z is a halogen or a nitrogen-containing group, X is hydrogen, halogen or alkyl, and W is hydrogen, alkyl, amino or halogen. The compounds have potent antineoplastic activity.

Chiral quinolone intermediates

Chiral compounds having the formulae STR1 useful in the synthesis of quinolone intermediates.